search
Back to results

Relationship Between PFTs and Pdi in DMD

Primary Purpose

Duchenne Muscular Dystrophy

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Esophageal Balloon
Gastric Balloon
Nasal Pressure Transducer
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Duchenne Muscular Dystrophy

Eligibility Criteria

6 Years - 25 Years (Child, Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of Duchenne muscular dystrophy

Exclusion Criteria:

  • Inability to follow verbal instructions

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Measurement of Pdi

    Measurement of SNIPs

    Arm Description

    Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.

    While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.

    Outcomes

    Primary Outcome Measures

    Evaluation of Pdi
    For all subjects Pdi (transdiaphragmatic pressure measures) will be assessed with gastric and esophageal balloons

    Secondary Outcome Measures

    Evaluation of SNIP
    For all subjects, SNIP (sniff nasal inspiratory pressures) will be assessed with a nasal pressure transducer
    Evaluation of FVC
    For all subjects, FVC (forced vital capacity) will be assessed with spirometry
    Evaluation of FEV1
    For all subjects, FEV1 (forced expiratory volume in 1 second) will be assessed with spirometry
    Evaluation of FEFmax
    For all subjects, FEFmax (maximal forced expiratory flow) will be assessed with spirometry
    Evaluation of FEF25-75
    For all subjects, FEF25-75 (the average forced expiratory flow during the mid (25 - 75%) portion of the FVC) will be assessed with spirometry
    Evaluation of FEF50
    For all subjects, FEF50 (forced expiratory flow at 50% of FVC) will be assessed with spirometry
    Evaluation of MIP
    For all subjects, MIP (maximal inspiratory pressure) will be assessed with spirometry
    Evaluation of MEP
    For all subjects, MEP (maximal expiratory pressure) will be assessed with spirometry

    Full Information

    First Posted
    October 12, 2017
    Last Updated
    May 8, 2018
    Sponsor
    University of Minnesota
    Collaborators
    Fairview Health Services
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03335384
    Brief Title
    Relationship Between PFTs and Pdi in DMD
    Official Title
    The Relationship Between Pulmonary Function Measures and Transdiaphragmatic Measures in Duchenne Muscular Dystrophy Subjects
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2018
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Study not approved
    Study Start Date
    May 1, 2018 (Actual)
    Primary Completion Date
    May 2018 (Anticipated)
    Study Completion Date
    May 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Minnesota
    Collaborators
    Fairview Health Services

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    A cross-sectional study to explore the relationship between clinically assessed pulmonary function test (PFT) measures and transdiaphragmatic (Pdi) measures in Duchenne muscular dystrophy (DMD) as well as to explore the relationship between sniff nasal inspiratory pressure (SNIP) and transdiaphragmatic (Pdi) measures in Duchenne muscular dystrophy.
    Detailed Description
    Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus and stomach through your nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus. Proper placement of the catheters will be determined using normal tidal breathing against an occluded mouthpiece with a nose clip. Once proper placement is ensured, the catheters will remain in place during your normal PFT maneuvers. Additionally, while the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a distal pressure measurement catheter to measure airway pressure. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Duchenne Muscular Dystrophy

    7. Study Design

    Primary Purpose
    Health Services Research
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Cross-sectional
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Measurement of Pdi
    Arm Type
    Experimental
    Arm Description
    Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.
    Arm Title
    Measurement of SNIPs
    Arm Type
    Experimental
    Arm Description
    While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Esophageal Balloon
    Intervention Description
    Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Gastric Balloon
    Intervention Description
    Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Nasal Pressure Transducer
    Intervention Description
    Pressure transducer inserted into nasal plug
    Primary Outcome Measure Information:
    Title
    Evaluation of Pdi
    Description
    For all subjects Pdi (transdiaphragmatic pressure measures) will be assessed with gastric and esophageal balloons
    Time Frame
    1 year
    Secondary Outcome Measure Information:
    Title
    Evaluation of SNIP
    Description
    For all subjects, SNIP (sniff nasal inspiratory pressures) will be assessed with a nasal pressure transducer
    Time Frame
    1 year
    Title
    Evaluation of FVC
    Description
    For all subjects, FVC (forced vital capacity) will be assessed with spirometry
    Time Frame
    1 year
    Title
    Evaluation of FEV1
    Description
    For all subjects, FEV1 (forced expiratory volume in 1 second) will be assessed with spirometry
    Time Frame
    1 year
    Title
    Evaluation of FEFmax
    Description
    For all subjects, FEFmax (maximal forced expiratory flow) will be assessed with spirometry
    Time Frame
    1 year
    Title
    Evaluation of FEF25-75
    Description
    For all subjects, FEF25-75 (the average forced expiratory flow during the mid (25 - 75%) portion of the FVC) will be assessed with spirometry
    Time Frame
    1 year
    Title
    Evaluation of FEF50
    Description
    For all subjects, FEF50 (forced expiratory flow at 50% of FVC) will be assessed with spirometry
    Time Frame
    1 year
    Title
    Evaluation of MIP
    Description
    For all subjects, MIP (maximal inspiratory pressure) will be assessed with spirometry
    Time Frame
    1 year
    Title
    Evaluation of MEP
    Description
    For all subjects, MEP (maximal expiratory pressure) will be assessed with spirometry
    Time Frame
    1 year

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    6 Years
    Maximum Age & Unit of Time
    25 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinical diagnosis of Duchenne muscular dystrophy Exclusion Criteria: Inability to follow verbal instructions
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Eric M Snyder, PhD
    Organizational Affiliation
    University of Minnesota
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Relationship Between PFTs and Pdi in DMD

    We'll reach out to this number within 24 hrs